Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fisher & Paykel HealthcareASX:FPH +0.61%88 Debt-to-Equity is 0.07 as of Mar. 2026, which is 22% below its 10-year median of 0.09. GuruFocus rates ASX:FPH with a GF Score™ of 88/100 and a GF Value™ of A$36.64 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 74.89% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Fisher & Paykel Healthcare's Debt-to-Equity or its related term are showing as below:
ASX:FPH'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.09 Max: 0.14
Current: 0.07
During the past 13 years, the highest Debt-to-Equity Ratio of Fisher & Paykel Healthcare was 0.14. The lowest was 0.06. And the median was 0.09.
ASX:FPH's Debt-to-Equity is ranked better than 74.89% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs ASX:FPH: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Fisher & Paykel Healthcare Debt-to-Equity Related Terms
Fisher & Paykel Healthcare Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:FPH vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a Debt-to-Equity of 0.07 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Fisher & Paykel Healthcare and its competitors. This is 22% below median its historical median of 0.09. Over the past decade, Fisher & Paykel Healthcare's Debt-to-Equity has ranged from 0.06 to 0.14. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #177 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 25.1%.
Is Fisher & Paykel Healthcare's Debt-to-Equity too high?
Fisher & Paykel Healthcare's current Debt-to-Equity of 0.07 is 22% below median its 10-year median of 0.09. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.14. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Fisher & Paykel Healthcare's value of 0.07 is 69.6% below this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #177 out of 705 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Fisher & Paykel Healthcare has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #177 out of 705 companies for Debt-to-Equity. This puts Fisher & Paykel Healthcare in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Fisher & Paykel Healthcare's value of 0.07 is 69.6% below this benchmark. Historically, Fisher & Paykel Healthcare's own Debt-to-Equity has ranged from 0.06 to 0.14 over the past decade. While the company's 10-year median is 0.09 vs. the industry median of 0.23, Fisher & Paykel Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current Debt-to-Equity of 0.07 is 69.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current Debt-to-Equity is 0.07, which is 22% below median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.64, compared to a current price of A$33.07 — trading 9.7% below its estimated fair value. The current Debt-to-Equity is 0.07, which is 22% below median its 10-year median of 0.09 and 69.6% below the Medical Devices & Instruments industry median of 0.23. Fisher & Paykel Healthcare's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current Debt-to-Equity is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$33.07 is trading 9.7% below its estimated GF Value™ of A$36.64.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for ASX:FPH:
Debt-to-Equity: 0.07 (22% below median its 10-year median of 0.09)
GF Value™: A$36.64 vs. price of A$33.07 (9.7% below fair value)
Industry Position: 69.6% below the Medical Devices & Instruments median (#177 of 705)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
88GF Score
Get the complete analysis for ASX:FPH
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
